Serotonin Reuptake Inhibitors are Associated with Less Amyloid‐β Burden Spatial Extent in Military Veterans with only PTSD, but not with TBI or Comorbid PTSD/TBI: Preliminary PET Findings from ADNI‐DOD Project

Some but not all studies suggested an association of serotonin reuptake inhibitors (SRIs) with a reduction in “magnitude” of amyloid‐β (Aβ) plaque burden. Using PET images from ADNI‐DOD and a voxel‐based Majority Count Algorithm (MCA), we demonstrated that cognitively unimpaired veterans with post‐traumatic stress disorder (PTSD) had significantly more cerebral voxels with lower rather than higher florbetapir standard uptake value ratios (voxel‐based P<0.05), reflecting Aβ burden reduction in “spatial extent” [Chen, AAIC 2018]). We postulated that this finding might relate their SRI use. Here, we investigate the impact of SRI use on the spatial extent of Aβ burden among ADNI‐DOD veterans with PTSD, comorbid PTSD and traumatic brain injury (TBI), and TBI.